Scientific Knowledge

Leadgene develops various monoclonal antibodies and recombinant proteins to meet the demands for clinical diagnosis.

Here we present our excellent customized services, including pharmacokinetic measurement (Biacore T200), antibody development, and antibody engineering. And we provide one-stop services from experimental design, customized service to data interpretation.

The experimental usage of secondary antibodies is to bind primary antibodies. With enzymatic, cross-linking or light-emitting labels on them, the binding effect of primary antibodies can be amplified and converted into many sorts of signals, then being processed by instruments for various purposes.

Leadgene's technical advantages lie in our protein antigen production methods, immunization of antibodies, and other downstream applications.

Recombinant protein expression is a biotechnological platform to generate a protein of interest by transmitting an exogeneous gene expression plasmid into a production cell factory, and through a series of culturing, harvesting, purifying and sometimes refolding process, the target protein is finally obtained.

Leadgene supported this research by providing essential reagents, including cytokines and lactoferin cocktail for PBMCs culture, and HyFect® DNA Transfection reagent to introduce scFv genes into cells for screening.

Immunohistochemistry (IHC) is a technique to identify target proteins or molecules in tissues using labeled antibodies. Using IHC, we have demonstrated that our IS mAbs can effectively recognize and bind to IS antigens regardless of varying IS concentrations and tissue type.

Leadgene’s Indoxyl Sulfate (IS) ELISA Kit employs a competitive ELISA test over the commonly used sandwich ELISA tests.

Among the different types of uremic toxins, protein-bound uremic toxins (PBUTs), such as indoxyl sulfate (IS), indole-acetic acid, and p-cresyl sulfate, threaten CKD patients. The PBUTs easily bind to proteins during blood circulation, so it is not possible to remove these toxins from patients via dialysis. The accumulation of PBUTs will further damage the renal function and the cardiovascular system.